Navigation Links
Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
Date:5/17/2009

iarrhea and, in the most serious cases, death. CDI typically develops from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, allowing C. difficile bacteria to flourish.

Current therapeutic options for CDI include metronidazole and oral vancomycin. However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of antibiotic administration.

Primary risk factors for CDI include broad-spectrum antibiotic use, advanced age (over 65), emerging hyper-virulent strains (NAP1/027, 078, 001) of C. difficile, and previous exposure to CDI that lead to recurrence. Higher incidence, increased treatment failures, and recurrence with standard therapies have resulted in greater awareness and concern of CDI among medical professionals and public health officials.

About Fidaxomicin

Fidaxomicin is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of Clostridium difficile. The narrow spectrum profile of fidaxomicin may eradicate Clostridium difficile selectively with minimal disruption to the normal intestinal flora. This may facilitate the return of the normal physiological conditions in the colon and reduce the probability of CDI recurrence.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is a
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... -- Compassion & Choices today is pleased to report that ... authorize the option of medical aid in dying for terminally ... The legislation, the End of ... adults with six months or less to live the option ... peacefully end an unbearable dying process. A vote on the ...
(Date:5/28/2015)... May 28, 2015 Today, the California State ... state prescription database before prescribing the most addictive medications ... overdose deaths. SB 482, authored by Sen. ... , will require prescribers to check the Controlled Substance ... II and III drugs, like OxyContin and other opioids, ...
(Date:5/28/2015)... May 28, 2015  The U.S. Department of Justice ... Inc. and Rehab Medical Inc. to resolve a lawsuit ... filing of a whistleblower lawsuit by two former employees ... under the direction of one of Orbit,s top executives, ... Orbit could obtain payment from Medicare for electric wheelchairs. ...
Breaking Medicine Technology:California Committee Sends Medical Aid-in-Dying Bill to Senate Floor 2California Committee Sends Medical Aid-in-Dying Bill to Senate Floor 3California Senate Approves Legislation Requiring Physicians To Check State Database Before Prescribing Powerful, Addictive Medications, Says Consumer Watchdog 2Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 2Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 4
(Date:5/28/2015)... Calif. (PRWEB) May 28, 2015 ... selection by ContentChecked (CNCK) as its agency of ... health and nutrition app, SugarChecked. SugarChecked is an ... better understand the potential sugars they are putting ... for the launch of SugarChecked, execute media initiatives ...
(Date:5/28/2015)... Restricting access to firearms for people ... that more clearly define alcohol misuse should be developed ... research and public policies by the UC Davis Violence ... 30 in the peer-reviewed journal Preventive Medicine , ... alcohol misuse in association with firearm access and use, ...
(Date:5/28/2015)... 28, 2015 AMVETS leaders this week ... winner Robert Davis of Newark, Del. AMVETS National Commander ... on winning the $10,000 sweepstakes grand prize. , AMVETS ... entries from around the country for prizes ranging from ... place on May 21 at the AMVETS National Headquarters ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 The ... has unveiled a dramatic billboard intended to educate the ... Located at the busy intersection of Market Street and ... which reads “If You’re for De-clawing Cats, Raise Your ... at the last joint, providing a graphic and anatomically-correct ...
(Date:5/28/2015)... 28, 2015 The CEO and Founder ... just launched blog series which provides analysis on the ... the “R. Bruce Dalglish” profile on Blogger.com, this instructive ... Dalglish’s corporate experience. , “Throughout my business career, ... have upon the overall success of businesses,” stated R. ...
Breaking Medicine News(10 mins):Health News:ContentChecked Selects PMBC Group To Launch New Nutrition App SugarChecked 2Health News:UC Davis Research Finds That Restricting Firearms Access for People who Misuse Alcohol May Prevent Violence 2Health News:UC Davis Research Finds That Restricting Firearms Access for People who Misuse Alcohol May Prevent Violence 3Health News:UC Davis Research Finds That Restricting Firearms Access for People who Misuse Alcohol May Prevent Violence 4Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 3Health News:R. Bruce Dalglish, CEO of Alliance Hospice, Introduces New Blog Series On Positive Corporate Culture 2
... Clinic researchers have found that a new combination ... or stabilized multiple myeloma for 76 percent of ... , Interim results of an ongoing clinical trial ... dexamethasone (pom/dex), were presented today at the 50th ...
... Professor Tim Eisen has expressed concerns that patients with ... effective, 20 year-old treatments because the National Institute for ... out using all four of the new treatments it ... BJU International , Professor Eisen, from the University ...
... www.amdl.com ) AMDL, Inc. (Amex: ... and the US, announced today the closing of the first tranche of a ... , In this first closing, AMDL sold $1,077,500 of ... of 24 months or the completion of a bank or credit facility of ...
... 9 The S trategies t o ... released the Obesity GPS - Guide for Policy and Program ... guide public and private decision makers as they determine the ... which costs the United States at least $92.6 billion annually, ...
... Annual Children,s Flu Vaccination Day to Help Increase Vaccination Rates and Reduce Flu-Related Illnesses ... , , To view the Multimedia News Release, ... , News Facts , , ... Families Fighting Flu (FFF) , together with the Centers for Disease Control ...
... 2050, up to 16 million people will have vision problems ... Americans with diabetic retinopathy is expected to increase from 5.5 ... a U.S. Centers for Disease Control and Prevention study. ... vessels in the retina, is the leading cause of blindness ...
Cached Medicine News:Health News:Drug combination improves or stabilizes disease for relapsed multiple myeloma patients 2Health News:UK kidney cancer patients face toxic, out-dated treatments with little hope of change 2Health News:UK kidney cancer patients face toxic, out-dated treatments with little hope of change 3Health News:AMDL Inc. Announces Closing of Private Placement Senior Notes 2Health News:AMDL Inc. Announces Closing of Private Placement Senior Notes 3Health News:STOP Obesity Alliance Releases Obesity GPS to Change America's Course in the Fight Against Overweight and Obesity 2Health News:STOP Obesity Alliance Releases Obesity GPS to Change America's Course in the Fight Against Overweight and Obesity 3Health News:STOP Obesity Alliance Releases Obesity GPS to Change America's Course in the Fight Against Overweight and Obesity 4Health News:Photo: Families Fighting Flu and CDC Encourage Parents to Vaccinate Kids Against Flu 2Health News:Photo: Families Fighting Flu and CDC Encourage Parents to Vaccinate Kids Against Flu 3Health News:Diabetic Eye Disease Rates Soaring 2
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Used to introduce large devices for vascular intervention....
Medicine Products: